Patents by Inventor Rajat Varma

Rajat Varma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-12 HETERODIMERIC FC-FUSION PROTEINS
    Publication number: 20230027540
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Application
    Filed: August 11, 2022
    Publication date: January 26, 2023
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • IL-12 HETERODIMERIC FC-FUSION PROTEINS
    Publication number: 20220396605
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Application
    Filed: April 11, 2022
    Publication date: December 15, 2022
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
    Patent number: 11524991
    Abstract: The present invention is directed to novel PD-1-targeted IL-15/R?-Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antigen binding domain. The PD-1-targeted IL-15/R?-Fc fusion proteins can be administered to a patient to treat cancer.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: December 13, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • IL-7-FC-fusion proteins
    Patent number: 11512122
    Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: November 29, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
  • TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
    Patent number: 11505595
    Abstract: The present invention is directed to novel targeted heterodimeric fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a TIM-3 antibody fragment-Fc fusion protein.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: November 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND GPC3
    Publication number: 20220306767
    Abstract: Provided herein are novel GPC3 binding domains, and antibodies that include such GPC3 binding domains (e.g., anti-GPC3×anti-CD3). Also provided herein are methods of using such antibodies for the treatment of GPC3-associated cancers.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 29, 2022
    Inventors: Alex Nisthal, Nargess Hassanzadeh-Kiabi, Katrina Bykova, Matthew J. Bernett, Rajat Varma
  • ENGINEERED IL-2 Fc FUSION PROTEINS
    Publication number: 20220213162
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 7, 2022
    Inventors: Matthew BERNETT, John DESJARLAIS, Rajat VARMA, Rumana RASHID
  • PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
    Patent number: 11377477
    Abstract: The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/R?-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: July 5, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Michael Hedvat, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Rajat Varma
  • IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS
    Publication number: 20220195048
    Abstract: The present invention is directed to novel IL15/IL15R? heterodimeric Fc fusion proteins.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 23, 2022
    Inventors: Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
  • IL-12 heterodimeric Fc-fusion proteins
    Patent number: 11358999
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12. Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: June 14, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid
  • Engineered IL-2 Fc fusion proteins
    Patent number: 11319355
    Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 3, 2022
    Assignee: Xencor, Inc.
    Inventors: Matthew Bernett, John Desjarlais, Rajat Varma, Rumana Rashid
  • TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS
    Publication number: 20220073588
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.
    Type: Application
    Filed: July 2, 2021
    Publication date: March 10, 2022
    Inventors: Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
  • IL-15/IL-15RA HETERODIMERIC FC FUSION PROTEINS AND USES THEREOF
    Publication number: 20220040264
    Abstract: The present invention is directed to novel IL-15/IL-15R? heterodimeric Fc fusion proteins and uses thereof. The IL-15/IL-15R? heterodimeric Fc fusion proteins can be administered to a patient to treat cancer. In some cases, the IL-15/IL-15R? heterodimeric Fc fusion protein is administered in combination with a checkpoint blockage antibody such as a PD-1 antibody.
    Type: Application
    Filed: March 22, 2021
    Publication date: February 10, 2022
    Inventors: Matthew Bernett, John Desjarlais, Rumana Rashid, Rajat Varma, Christine Bonzon
  • TARGETED IL-12 HETERODIMERIC FC-FUSION PROTEINS
    Publication number: 20210355185
    Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.
    Type: Application
    Filed: October 2, 2020
    Publication date: November 18, 2021
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid, Nargess Hassanzadeh-Kiabi, Michael Hedvat, Eric Chang
  • Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
    Patent number: 11084863
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an antigen binding domain Fc fusion proteins. In some instances, the antigen binding domain binds to CD8, NKG2A, or NKG2D.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 10, 2021
    Assignee: Xencor, Inc.
    Inventors: Matthew J. Bernett, John Desjarlais, Rajat Varma, Suzanne Schubbert, Juan Diaz
  • PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS WITH IMPROVED PROPERTIES
    Publication number: 20210230243
    Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
    Type: Application
    Filed: October 9, 2020
    Publication date: July 29, 2021
    Inventors: John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
  • UNTARGETED AND TARGETED IL-10 FC-FUSION PROTEINS
    Publication number: 20210171596
    Abstract: The present invention provides untargeted and targeted IL-10-Fc fusion proteins, compositions and methods of use thereof. The targeted IL-10-Fc fusion proteins includes those that bind PD-1, TIGIT, CD8 and NKG2D.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 10, 2021
    Inventors: Gregory Moore, Rajat Varma, Yoon Kyung Kim, Rumana Rashid, Eric W. Chang, Alex Nisthal, Juan Diaz, Matthew Bernett, Michael Hedvat
  • IL-7-FC-FUSION PROTEINS
    Publication number: 20210070824
    Abstract: Provided herein are dimeric IL-7-Fc fusion proteins that include Fc domains and one or more IL-7s. Also provided herein are variant IL-7s with modifications to reduce heterogeneity and/or reduced affinity/potency. Such variant IL-7s are useful, for example, in the subject dimeric IL-7-Fc fusion proteins. The dimeric IL-7-Fc fusion proteins can be used for applications where increased IL-7 activity is useful, for example, for increasing the proliferation of lymphocyte populations in mounting an anti-tumor response in a subject in need thereof.
    Type: Application
    Filed: May 15, 2020
    Publication date: March 11, 2021
    Inventors: Matthew Bernett, John Desjarlais, Suzanne Schubbert, Christine Bonzon, Rajat Varma, Raphael Clynes
  • TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15/IL-15RA AND NKG2D ANTIGEN BINDING DOMAINS
    Publication number: 20200247862
    Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.
    Type: Application
    Filed: December 20, 2019
    Publication date: August 6, 2020
    Inventors: Matthew J. Bernett, John R. Desjarlais, Rajat Varma, Gregory Moore, Juan Diaz, Alex Nisthal, Ke Liu, Rumana Rashid, Eric Chang
  • IL-12 HETERODIMERIC FC-FUSION PROTEINS
    Publication number: 20200216509
    Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12. Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.
    Type: Application
    Filed: October 3, 2019
    Publication date: July 9, 2020
    Inventors: Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Nargess Hassanzadeh-Kiabi, Rumana Rashid